From discovery to licensure, the Adjuvant System story
Adjuvants are substances added to vaccines to improve their immunogenicity. Used for more than 80 years, aluminum, the first adjuvant in human vaccines, proved insufficient to develop vaccines that could protect against new challenging pathogens such as HIV and malaria. New adjuvants and new combina...
Gespeichert in:
| Veröffentlicht in: | Human vaccines & immunotherapeutics 2017-01, Vol.13 (1), p.19-33 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 33 |
|---|---|
| container_issue | 1 |
| container_start_page | 19 |
| container_title | Human vaccines & immunotherapeutics |
| container_volume | 13 |
| creator | Garçon, Nathalie Di Pasquale, Alberta |
| description | Adjuvants are substances added to vaccines to improve their immunogenicity. Used for more than 80 years, aluminum, the first adjuvant in human vaccines, proved insufficient to develop vaccines that could protect against new challenging pathogens such as HIV and malaria. New adjuvants and new combinations of adjuvants (Adjuvant Systems) have opened the door to the delivery of improved and new vaccines against re-emerging and difficult pathogens. Adjuvant Systems concept started through serendipity. The access to new developments in technology, microbiology and immunology have been instrumental for the dicephering of what they do and how they do it. This knowledge opens the door to more rational vaccine design with implications for developing new and better vaccines. |
| doi_str_mv | 10.1080/21645515.2016.1225635 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_proquest_miscellaneous_1842539337</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_c7abb8a8e65141699ea9a290584c342f</doaj_id><sourcerecordid>1842539337</sourcerecordid><originalsourceid>FETCH-LOGICAL-c600t-3fcf345b9c6edede3ae1e98a72be05846435315080d0fc5d88bbda14e1d082053</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhiMEolXpTwDlyIFd_B37gqgq-iFV4gBI3KyJPWmzSuJiO4vy7_Gy2xW9YB88Gr_zjMdvVb2lZE2JJh8ZVUJKKteMULWmjEnF5YvqdJdfSSl-vjzGVJ5U5yltSFkNYUKp19UJaxRXxOjTSl3FMNa-Ty5sMS51DvXQO5zSHPFDnR-wvvCbeQtTrr8tKeNYpxzi8qZ61cGQ8PxwnlU_rr58v7xZ3X29vr28uFs5RUhe8c51XMjWOIW-bA5I0WhoWItEaqEEl5zKMpInnZNe67b1QAVSTzQjkp9Vt3uuD7Cxj7EfIS42QG__JkK8txBz7wa0roG21aBRSSqoMgbBADO7No4L1hXWpz3rcW5H9GXIHGF4Bn1-M_UP9j5srWS64cQUwPsDIIZfM6Zsx_JvOAwwYZiTpVowyQ3nTZHKvdTFkFLE7tiGEruz0D5ZaHcW2oOFpe7dv288Vj0ZVgSf94J-6kIc4XeIg7cZliHELsLk-mT5_3v8ASqcqps</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1842539337</pqid></control><display><type>article</type><title>From discovery to licensure, the Adjuvant System story</title><source>MEDLINE</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Garçon, Nathalie ; Di Pasquale, Alberta</creator><creatorcontrib>Garçon, Nathalie ; Di Pasquale, Alberta</creatorcontrib><description>Adjuvants are substances added to vaccines to improve their immunogenicity. Used for more than 80 years, aluminum, the first adjuvant in human vaccines, proved insufficient to develop vaccines that could protect against new challenging pathogens such as HIV and malaria. New adjuvants and new combinations of adjuvants (Adjuvant Systems) have opened the door to the delivery of improved and new vaccines against re-emerging and difficult pathogens. Adjuvant Systems concept started through serendipity. The access to new developments in technology, microbiology and immunology have been instrumental for the dicephering of what they do and how they do it. This knowledge opens the door to more rational vaccine design with implications for developing new and better vaccines.</description><identifier>ISSN: 2164-5515</identifier><identifier>EISSN: 2164-554X</identifier><identifier>DOI: 10.1080/21645515.2016.1225635</identifier><identifier>PMID: 27636098</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><subject>adaptive immune response ; adjuvant ; adjuvant system ; adjuvanted vaccine ; Adjuvants, Immunologic ; Animals ; Drug Approval ; Drug Discovery ; Humans ; innate immune response ; Licensure ; Reviews ; vaccine development</subject><ispartof>Human vaccines & immunotherapeutics, 2017-01, Vol.13 (1), p.19-33</ispartof><rights>2017 The Author(s). Published with license by Taylor & Francis. © GSK Biologicals SA. 2017</rights><rights>2017 The Author(s). Published with license by Taylor & Francis. 2017 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c600t-3fcf345b9c6edede3ae1e98a72be05846435315080d0fc5d88bbda14e1d082053</citedby><cites>FETCH-LOGICAL-c600t-3fcf345b9c6edede3ae1e98a72be05846435315080d0fc5d88bbda14e1d082053</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287309/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287309/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27636098$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Garçon, Nathalie</creatorcontrib><creatorcontrib>Di Pasquale, Alberta</creatorcontrib><title>From discovery to licensure, the Adjuvant System story</title><title>Human vaccines & immunotherapeutics</title><addtitle>Hum Vaccin Immunother</addtitle><description>Adjuvants are substances added to vaccines to improve their immunogenicity. Used for more than 80 years, aluminum, the first adjuvant in human vaccines, proved insufficient to develop vaccines that could protect against new challenging pathogens such as HIV and malaria. New adjuvants and new combinations of adjuvants (Adjuvant Systems) have opened the door to the delivery of improved and new vaccines against re-emerging and difficult pathogens. Adjuvant Systems concept started through serendipity. The access to new developments in technology, microbiology and immunology have been instrumental for the dicephering of what they do and how they do it. This knowledge opens the door to more rational vaccine design with implications for developing new and better vaccines.</description><subject>adaptive immune response</subject><subject>adjuvant</subject><subject>adjuvant system</subject><subject>adjuvanted vaccine</subject><subject>Adjuvants, Immunologic</subject><subject>Animals</subject><subject>Drug Approval</subject><subject>Drug Discovery</subject><subject>Humans</subject><subject>innate immune response</subject><subject>Licensure</subject><subject>Reviews</subject><subject>vaccine development</subject><issn>2164-5515</issn><issn>2164-554X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>EIF</sourceid><sourceid>DOA</sourceid><recordid>eNp9kU1v1DAQhiMEolXpTwDlyIFd_B37gqgq-iFV4gBI3KyJPWmzSuJiO4vy7_Gy2xW9YB88Gr_zjMdvVb2lZE2JJh8ZVUJKKteMULWmjEnF5YvqdJdfSSl-vjzGVJ5U5yltSFkNYUKp19UJaxRXxOjTSl3FMNa-Ty5sMS51DvXQO5zSHPFDnR-wvvCbeQtTrr8tKeNYpxzi8qZ61cGQ8PxwnlU_rr58v7xZ3X29vr28uFs5RUhe8c51XMjWOIW-bA5I0WhoWItEaqEEl5zKMpInnZNe67b1QAVSTzQjkp9Vt3uuD7Cxj7EfIS42QG__JkK8txBz7wa0roG21aBRSSqoMgbBADO7No4L1hXWpz3rcW5H9GXIHGF4Bn1-M_UP9j5srWS64cQUwPsDIIZfM6Zsx_JvOAwwYZiTpVowyQ3nTZHKvdTFkFLE7tiGEruz0D5ZaHcW2oOFpe7dv288Vj0ZVgSf94J-6kIc4XeIg7cZliHELsLk-mT5_3v8ASqcqps</recordid><startdate>20170102</startdate><enddate>20170102</enddate><creator>Garçon, Nathalie</creator><creator>Di Pasquale, Alberta</creator><general>Taylor & Francis</general><general>Taylor & Francis Group</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20170102</creationdate><title>From discovery to licensure, the Adjuvant System story</title><author>Garçon, Nathalie ; Di Pasquale, Alberta</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c600t-3fcf345b9c6edede3ae1e98a72be05846435315080d0fc5d88bbda14e1d082053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>adaptive immune response</topic><topic>adjuvant</topic><topic>adjuvant system</topic><topic>adjuvanted vaccine</topic><topic>Adjuvants, Immunologic</topic><topic>Animals</topic><topic>Drug Approval</topic><topic>Drug Discovery</topic><topic>Humans</topic><topic>innate immune response</topic><topic>Licensure</topic><topic>Reviews</topic><topic>vaccine development</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Garçon, Nathalie</creatorcontrib><creatorcontrib>Di Pasquale, Alberta</creatorcontrib><collection>Taylor & Francis Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Human vaccines & immunotherapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Garçon, Nathalie</au><au>Di Pasquale, Alberta</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>From discovery to licensure, the Adjuvant System story</atitle><jtitle>Human vaccines & immunotherapeutics</jtitle><addtitle>Hum Vaccin Immunother</addtitle><date>2017-01-02</date><risdate>2017</risdate><volume>13</volume><issue>1</issue><spage>19</spage><epage>33</epage><pages>19-33</pages><issn>2164-5515</issn><eissn>2164-554X</eissn><abstract>Adjuvants are substances added to vaccines to improve their immunogenicity. Used for more than 80 years, aluminum, the first adjuvant in human vaccines, proved insufficient to develop vaccines that could protect against new challenging pathogens such as HIV and malaria. New adjuvants and new combinations of adjuvants (Adjuvant Systems) have opened the door to the delivery of improved and new vaccines against re-emerging and difficult pathogens. Adjuvant Systems concept started through serendipity. The access to new developments in technology, microbiology and immunology have been instrumental for the dicephering of what they do and how they do it. This knowledge opens the door to more rational vaccine design with implications for developing new and better vaccines.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>27636098</pmid><doi>10.1080/21645515.2016.1225635</doi><tpages>15</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2164-5515 |
| ispartof | Human vaccines & immunotherapeutics, 2017-01, Vol.13 (1), p.19-33 |
| issn | 2164-5515 2164-554X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1842539337 |
| source | MEDLINE; PubMed Central; Alma/SFX Local Collection |
| subjects | adaptive immune response adjuvant adjuvant system adjuvanted vaccine Adjuvants, Immunologic Animals Drug Approval Drug Discovery Humans innate immune response Licensure Reviews vaccine development |
| title | From discovery to licensure, the Adjuvant System story |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T07%3A19%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=From%20discovery%20to%20licensure,%20the%20Adjuvant%20System%20story&rft.jtitle=Human%20vaccines%20&%20immunotherapeutics&rft.au=Gar%C3%A7on,%20Nathalie&rft.date=2017-01-02&rft.volume=13&rft.issue=1&rft.spage=19&rft.epage=33&rft.pages=19-33&rft.issn=2164-5515&rft.eissn=2164-554X&rft_id=info:doi/10.1080/21645515.2016.1225635&rft_dat=%3Cproquest_doaj_%3E1842539337%3C/proquest_doaj_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1842539337&rft_id=info:pmid/27636098&rft_doaj_id=oai_doaj_org_article_c7abb8a8e65141699ea9a290584c342f&rfr_iscdi=true |